Traditional pharmacotherapy primarily alters synaptic transmission. Neuromodulation platforms (such as rTMS, ECT, and invasive stimulation) primarily alter excitability in specific cortical or subcortical targets. But most existing approaches were not originally designed to deliberately recalibrate the balance and interaction of large-scale networks such as DMN, CEN/FPN, and SN.
Поиск
Недавние
  • Salience Clinical, LLC
    Advances in molecular diagnostics, computational neuroscience, fluid biomarkers, and digital phenotyping are enabling CNS disorders to be reclassified according to biological signatures, neural circuit dysfunction, and measurable disease trajectories. Precision neurology is no longer a future concept; it is becoming the operational foundation of successful CNS development strategy.
    https://salienceclinical.com/
    Salience Clinical, LLC Advances in molecular diagnostics, computational neuroscience, fluid biomarkers, and digital phenotyping are enabling CNS disorders to be reclassified according to biological signatures, neural circuit dysfunction, and measurable disease trajectories. Precision neurology is no longer a future concept; it is becoming the operational foundation of successful CNS development strategy. https://salienceclinical.com/
    0 Комментарии 0 Поделились 0 Отзывы
  • Salience Clinical, LLC
    For decades, major depressive disorder (MDD) has been framed as a disorder of neurotransmitters primarily serotonin, norepinephrine, and dopamine. This model enabled meaningful therapeutic progress, but its limits are increasingly clear. A large proportion of patients do not achieve sustained remission. Treatment resistance remains common, and relapse rates are high even among responders. These realities suggest that incremental adjustments to synaptic signaling have reached a practical ceiling in their ability to reshape long-term outcomes.
    https://salienceclinical.com/
    Salience Clinical, LLC For decades, major depressive disorder (MDD) has been framed as a disorder of neurotransmitters primarily serotonin, norepinephrine, and dopamine. This model enabled meaningful therapeutic progress, but its limits are increasingly clear. A large proportion of patients do not achieve sustained remission. Treatment resistance remains common, and relapse rates are high even among responders. These realities suggest that incremental adjustments to synaptic signaling have reached a practical ceiling in their ability to reshape long-term outcomes. https://salienceclinical.com/
    0 Комментарии 0 Поделились 0 Отзывы
  • Denis Katz, MD


    Alzheimer’s disease (AD) remains one of the most capital-intensive and failure-prone areas in biopharma. Decades of high-profile setbacks created what many termed the Alzheimer’s graveyard. Yet recent approvals targeting amyloid biology have demonstrated a critical shift: regulatory pathways are viable but only when programs are designed with precision and foresight.
    https://salienceclinical.com/
    Denis Katz, MD Alzheimer’s disease (AD) remains one of the most capital-intensive and failure-prone areas in biopharma. Decades of high-profile setbacks created what many termed the Alzheimer’s graveyard. Yet recent approvals targeting amyloid biology have demonstrated a critical shift: regulatory pathways are viable but only when programs are designed with precision and foresight. https://salienceclinical.com/
    0 Комментарии 0 Поделились 0 Отзывы
  • Denis Katz Medical Affairs
    Today, central nervous system (CNS) disorders are being redefined through molecular signatures, circuit-level dysfunction, and continuously captured digital phenotypes. This shift is not incremental it fundamentally alters how therapies must be discovered, developed, and approved.
    https://salienceclinical.com/
    Denis Katz Medical Affairs Today, central nervous system (CNS) disorders are being redefined through molecular signatures, circuit-level dysfunction, and continuously captured digital phenotypes. This shift is not incremental it fundamentally alters how therapies must be discovered, developed, and approved. https://salienceclinical.com/
    0 Комментарии 0 Поделились 0 Отзывы
  • Salience Clinical, LLC
    Cell-based therapies and advanced biologics are redefining what is possible in the treatment of neurological disease. Unlike traditional pharmacologic approaches, these modalities aim to directly influence disease biology through neuronal replacement, gene correction, immune modulation, or sustained protein expression.
    https://salienceclinical.com/
    Salience Clinical, LLC Cell-based therapies and advanced biologics are redefining what is possible in the treatment of neurological disease. Unlike traditional pharmacologic approaches, these modalities aim to directly influence disease biology through neuronal replacement, gene correction, immune modulation, or sustained protein expression. https://salienceclinical.com/
    0 Комментарии 0 Поделились 0 Отзывы
  • Denis Katz Clinical Consultant
    CNS disorders are now being redefined through molecular signatures, circuit-level dysfunction, and digital phenotypes. This is not a technological evolution it is a structural reset of how drugs are developed, evaluated, and approved.
    https://salienceclinical.com/
    Denis Katz Clinical Consultant CNS disorders are now being redefined through molecular signatures, circuit-level dysfunction, and digital phenotypes. This is not a technological evolution it is a structural reset of how drugs are developed, evaluated, and approved. https://salienceclinical.com/
    0 Комментарии 0 Поделились 0 Отзывы
  • Denis Katz, MD
    Alzheimer’s disease (AD) drug development remains the most capital-intensive and failure-prone domain in biopharma. The so-called “Alzheimer’s graveyard” reflects decades of scientific promise undermined by regulatory, operational, and strategic misalignment.
    https://salienceclinical.com/
    Denis Katz, MD Alzheimer’s disease (AD) drug development remains the most capital-intensive and failure-prone domain in biopharma. The so-called “Alzheimer’s graveyard” reflects decades of scientific promise undermined by regulatory, operational, and strategic misalignment. https://salienceclinical.com/
    0 Комментарии 0 Поделились 0 Отзывы
  • Salience Clinical, LLC
    Advances in high-resolution functional MRI, multimodal imaging, and computational modeling over the past decade have significantly reshaped our understanding of depression. Rather than viewing major depressive disorder as a localized or purely neurochemical condition, it is now increasingly recognized as a disorder of distributed brain network dynamics.
    https://salienceclinical.com/
    Salience Clinical, LLC Advances in high-resolution functional MRI, multimodal imaging, and computational modeling over the past decade have significantly reshaped our understanding of depression. Rather than viewing major depressive disorder as a localized or purely neurochemical condition, it is now increasingly recognized as a disorder of distributed brain network dynamics. https://salienceclinical.com/
    0 Комментарии 0 Поделились 0 Отзывы
  • Denis Katz, MD
    Alzheimer’s disease (AD) drug development remains the highest-stakes arena in biopharma. While the "Alzheimer’s Graveyard" is littered with multi-billion dollar failures, a new era of amyloid and tau-targeting therapies has proven that the regulatory path is navigable but only for those with a disciplined risk architecture.
    https://salienceclinical.com/
    Denis Katz, MD Alzheimer’s disease (AD) drug development remains the highest-stakes arena in biopharma. While the "Alzheimer’s Graveyard" is littered with multi-billion dollar failures, a new era of amyloid and tau-targeting therapies has proven that the regulatory path is navigable but only for those with a disciplined risk architecture. https://salienceclinical.com/
    0 Комментарии 0 Поделились 0 Отзывы
  • The Architectural Turn in Depression Why Network Topology Will Redefine CNS Strategy
    By Denis Katz, MD, MHA Founder, Salience Clinical For decades, psychiatry has framed major depressive disorder (MDD) as a disorder of chemistry, an imbalance of serotonin, norepinephrine, or dopamine. That model produced meaningful therapeutic advances, yet it has not consistently delivered durable remission for a substantial proportion of patients. Roughly one-third remain treatment resistant,...
    0 Комментарии 0 Поделились 0 Отзывы
Смотреть ещё
VintFint https://vintfint.com